Idera Pharmaceuticals, Inc. (IDRA)
(Delayed Data from NSDQ)
$3.57 USD
+0.51 (16.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Aceragen, Inc. [IDRA]
Reports for Purchase
Showing records 1 - 20 ( 169 total )
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
ILLUMINATE-301 Fail Not Very Enlightening; Downgrading to NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Negative Readout From Tilsotolimod Phase 3 Study; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Phase 3 Tilsotolimod Data Imminent
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Phase 3 Results Expected in March; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
ILLUMINATE-301 Remains on Track to Report in 1Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ILLUMINATE-301 Remains on Track for 1Q:21 Readout
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Pivotal Phase 3 Results Expected in 1Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 3 Readout Remains On Track for Q1:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Initial Results From ILLUMINATE-206 Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Quick Look at ILLUMINATE-206 in MSS-CRC; Additional Cohort Planned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Cash Runway Tight But Sufficient to Reach Critical Readouts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Aceragen, Inc.
Industry: Medical - Biomedical and Genetics
Cash Runway Extended Until 2Q21; Eyes on Phase 3 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department